全文获取类型
收费全文 | 24377篇 |
免费 | 1768篇 |
国内免费 | 732篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 278篇 |
妇产科学 | 151篇 |
基础医学 | 1539篇 |
口腔科学 | 287篇 |
临床医学 | 2007篇 |
内科学 | 2884篇 |
皮肤病学 | 311篇 |
神经病学 | 1884篇 |
特种医学 | 256篇 |
外国民族医学 | 1篇 |
外科学 | 865篇 |
综合类 | 2530篇 |
一般理论 | 3篇 |
预防医学 | 1811篇 |
眼科学 | 171篇 |
药学 | 9731篇 |
7篇 | |
中国医学 | 1382篇 |
肿瘤学 | 730篇 |
出版年
2024年 | 70篇 |
2023年 | 410篇 |
2022年 | 635篇 |
2021年 | 879篇 |
2020年 | 874篇 |
2019年 | 949篇 |
2018年 | 975篇 |
2017年 | 995篇 |
2016年 | 857篇 |
2015年 | 835篇 |
2014年 | 1767篇 |
2013年 | 2562篇 |
2012年 | 1626篇 |
2011年 | 1697篇 |
2010年 | 1260篇 |
2009年 | 1089篇 |
2008年 | 995篇 |
2007年 | 1076篇 |
2006年 | 899篇 |
2005年 | 773篇 |
2004年 | 637篇 |
2003年 | 594篇 |
2002年 | 431篇 |
2001年 | 402篇 |
2000年 | 320篇 |
1999年 | 262篇 |
1998年 | 236篇 |
1997年 | 231篇 |
1996年 | 224篇 |
1995年 | 195篇 |
1994年 | 159篇 |
1993年 | 193篇 |
1992年 | 188篇 |
1991年 | 139篇 |
1990年 | 134篇 |
1989年 | 109篇 |
1988年 | 122篇 |
1987年 | 82篇 |
1986年 | 88篇 |
1985年 | 128篇 |
1984年 | 114篇 |
1983年 | 85篇 |
1982年 | 94篇 |
1981年 | 61篇 |
1980年 | 71篇 |
1979年 | 56篇 |
1978年 | 64篇 |
1977年 | 56篇 |
1976年 | 47篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
2.
3.
良性前列腺增生(BPH)是老年男性常见的泌尿系统疾病,其发病与前列腺慢性炎症之间存在显著相关。感染因子、尿液返流、代谢综合征、衰老过程和自身免疫应答在内的几种刺激,通过相应分子途径引起前列腺免疫细胞的组织定位和组成成分发生广泛改变,从而导致免疫系统失调,之后引发的组织损伤和缓慢愈合,导致了BPH发生和进展。本文通过总结良性前列腺增生与前列腺慢性炎症的相关性的临床研究结果,前列腺免疫细胞在病理生理机制层面与前两者之间的内在联系,以及抗炎药物对BPH-LUTS的干预作用,以其为BPH-LUTS的药物研发提供参考。 相似文献
4.
Cameron Duff 《Addiction (Abingdon, England)》2020,115(7):1378-1381
In 1998 Howard Parker, Judith Aldridge & Fiona Measham published Illegal Leisure, a ground‐breaking study of profound changes in British youth cultures in the 1990s, and the place of drugs and drug use in these upheavals. This work introduced the ‘normalization thesis’ to the social sciences, offering a novel vocabulary for re‐imagining the normative character of young people's attitudes towards and experiences of illicit drug use. Arriving at the dawn of the new century, the book offered a thoroughgoing re‐thinking of the character of youth cultures at a time of great social, cultural, economic and technological disruption. In so doing, the book deftly anticipated many of the most interesting currents of critical drug studies that followed. 相似文献
5.
Cristiano Colalto 《Drug development research》2020,81(8):950-968
COVID-19 is a novel coronavirus disease with a higher incidence of bilateral pneumonia and pleural effusion. The high pulmonary tropism and contagiousness of the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have stimulated new approaches to combat its widespread diffusion. In developing new pharmacological strategies, the chemical characteristic of volatility can add therapeutic value to the hypothetical drug candidate. Volatile molecules are characterized by a high vapor pressure and are consequently easily exhaled by the lungs after ingestion. This feature could be exploited from a pharmacological point of view, reaching the site of action in an uncommon way but allowing for drug delivery. In this way, a hypothetical molecule for COVID-19 should have a balance between its lung exhalation characteristics and both antiviral and anti-inflammatory pharmacological action. Here, the feasibility, advantages, and disadvantages of a therapy based on oral administration of possible volatile drugs for COVID-19 will be discussed. Both aerosolized antiviral therapy and oral intake of volatile molecules are briefly reviewed, and an evaluation of 1,8-cineole is provided in view of a possible clinical use and also for asymptomatic COVID-19. 相似文献
6.
7.
摘要:抗生素的研发与使用有效杀灭和抑制了众多病原菌,挽救了无数人的生命,但由于抗生素的不合理使用,导致细菌耐
药不断出现,耐药菌的感染已严重地威胁人类的生命健康。为此,本文主要对近年来临床上常用的抗生素如β-内酰胺类、喹诺酮
类、氨基糖苷类药物以及新型抗菌药物如抗菌肽和纳米颗粒的应用研究进行总结分析与探讨,为临床上治疗疾病提供一些参考。 相似文献
8.
9.
我国奶牛养殖规模不断扩大,奶业产值比重逐步提高,给奶牛疫病防治带来巨大压力。奶牛乳房炎及细菌性肺炎等呼吸系统疾病和细菌性肠炎等消化系统疾病最为常见,抗菌药物的使用成为主要防治手段。但抗菌药物的不当使用易使细菌产生耐药性,增加临床治疗的成本和难度,危害我国奶牛产业发展。本文对截至2021年7月我国和美国、英国、日本、欧盟批准用于奶牛的抗菌药物产品进行整理、统计与分析,包括抗菌药物的分类、剂型以及适应证等,旨在为我国奶牛用抗菌药物管理、合理用药和新兽药开发提供参考。 相似文献
10.
《Value in health》2022,25(12):1958-1966
ObjectivesNational health technology assessments (HTAs) across Europe show differences in evidentiary requirements from assessments by the European Medicines Agency (EMA), affecting time to patient access for drugs after marketing authorization. This article analyzes the differences between EMA and HTA bodies’ evidentiary requirements for oncology drugs and provides recommendations on potential further alignment to minimize and optimally manage the remaining differences.MethodsInterviews were performed with representatives and drug assessment experts from EMA and HTA bodies to identify evidentiary requirements for several subdomains and collect recommendations for potentially more efficiently addressing differences. A comparative analysis of acceptability of the evidence by EMA and the HTA bodies and for potential further alignment between both authorities was conducted.ResultsAcceptability of available evidence was higher for EMA than HTA bodies. HTA bodies and EMA were aligned on evidentiary requirements in most cases. The subdomains showing notable differences concerned the acceptance of limitation of the target population and extrapolation of target populations, progression-free survival and (other) surrogate endpoints as outcomes, cross-over designs, short trial duration, and clinical relevance of the effect size. Recommendations for reducing or optimally managing differences included joint early dialogues, joint relative effectiveness assessments, and the use of managed entry agreements.ConclusionsDifferences between assessments of EMA and HTA bodies were identified in important areas of evidentiary requirements. Increased alignment between EMA and HTA bodies is suggested and recommendations for realization are discussed. 相似文献